within Pharmacolibrary.Drugs.ATC.V;

model V03AE10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 0.01,
    adminCount     = 1,
    Vd             = 0,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Sodium zirconium cyclosilicate (SZC) is a non-absorbed, inorganic cation exchange compound used for the treatment of hyperkalemia (elevated serum potassium) in adults. It selectively captures potassium ions in exchange for sodium and hydrogen ions in the gastrointestinal tract, thereby lowering serum potassium. The drug is currently approved and used clinically for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic profile for adult patients with hyperkalemia; healthy individuals; both sexes; data from clinical trials.</p><h4>References</h4><ol><li>David K Packham, Mikhail Kosiborod,Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS-9] in the treatment of hyperkalemia.,Expert opinion on drug metabolism & toxicology,2016<a href='https://pubmed.ncbi.nlm.nih.gov/26998854/'>https://pubmed.ncbi.nlm.nih.gov/26998854/</a></li><li>Chandan Takkar, Tareq Nassar, Wajeh Qunibi,An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.,Expert opinion on pharmacotherapy,2021<a href='https://pubmed.ncbi.nlm.nih.gov/32892634/'>https://pubmed.ncbi.nlm.nih.gov/32892634/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V03AE10;
